Eli Lilly's New Weight Loss Drug Shows Significant Results in Clinical Trial
Eli Lilly recently released results from its phase three TRIUMPH-2 trial for retatrutide, a new weight-loss drug. Participants taking the highest dose (12 mg) lost an average of 49.6 pounds or 20.8% of their body weight, with some losing nearly 61 pounds if they had a BMI over 35%. More than half no longer met obesity criteria by study's end. The drug also reduced A1C levels in participants with type 2 diabetes and showed benefits for knee arthritis pain and sleep apnea. Retatrutide outperformed Lilly’s existing weight-loss drugs like tirzepatide (Zepbound) and potential competitors such as Wegovy and Ozempic. Lilly plans to submit a biologics license application with the FDA, potentially reshaping the obesity drug market. The results have already fueled speculation about retatrutide's blockbuster status.
Tickers: $LLY
Topics: clinical trials obesity treatment type 2 diabetes weight loss drugs